Volume surge masks a profit cliff; guidance quietly shelved

Unpassable input cost inflation. Metals and EVA prices spiked (war-driven), adding ₹1.86/Wp to module cost. Only cell costs are contractually escalated in 88% of the order book; balance-of-raw-materials (BORM) — metals 35%, EVA 12%, freight — are unprotected. Oversupply in the 210 GW national module market prevented any price recovery.

Inventory cost drag from Q4 FY26. Chinese cell costs spiked in Q4 FY26; higher-cost inventory flowed through P&L in Q1. This will reverse as lower-cost procurement normalizes, but Q1 was distorted by the tail.

Industry oversupply destroying pricing power. With 210 GW of domestic module capacity chasing 45–50 GW of annual demand, no player — Vikram or peers — can pass through cost inflation to large accounts (utilities, IPPs). Even peers with captive cell plants reported only 1–2% margin erosion; Vikram's 50% decline reflects the same oversupply, compounded by the absence of in-house cells until Q4 FY27.

FY27 EBITDA guidance withdrawn. Prior target ₹1,500–1,600 Cr is now effectively abandoned. Q1 run-rate annualizes to ~₹504 Cr — a 66% shortfall. No revised number offered; management deferring to H1 for clarity.

DCR business promoted to cornerstone of margin recovery. Prior call emphasized capex and backward integration as primary levers. Now DCR ramp (currently 76 MW, expected to 2–2.5x quarterly) is the centerpiece for near-term margin lift. But base is too small to move the needle in FY27.

Tone shifted from confident to defensive. CEO repeated 'allow one more quarter for clarity' 6+ times on the call. Management openly acknowledged cost pass-through failure and the structural nature of oversupply. Less a data update, more a credibility reset.

Capex phasing brought forward (positive). Wafer-ingot capacity increased 6 GW → 9 GW; cell plant on track Q4 FY27 (not Dec–Mar as prior guidance). Gangaikondan module facility delivered first unit June 29, on promised date. Execution discipline proven, but capex ₹10,000 Cr over FY27–28 will require levering to 70:30 debt-equity.

Order book composition shifting mid-market and distribution. 7.9 GW order book now includes larger mid-market, distribution channels (119+ distributors, 757 dealers). Pricing ₹0.50–1.50/Wp premium over large accounts. Mix is positive, but unproven at scale and offers no relief to FY27 margins.

Backward integration thesis is structurally sound. Cell plant (9 GW) on track Q4 FY27; wafer-ingot (9 GW) groundbreaking next month. In-house cells will capture 2–3% margin internally, structurally lifting EBITDA per watt from current ₹1.25/Wp toward historical ₹1.50–2.00/Wp. Ecovadis Platinum rating (top 1% globally) supports global buyer credibility post-integration.

Capex execution proof. Gangaikondan module facility first unit rolled June 29, on promised date. ₹500 Cr deployed Q1 per plan; no cost overruns to date. If this discipline holds through wafer-ingot groundbreaking and cell plant ramp, capex ₹10,000 Cr over FY27–28 is achievable at 70:30 debt-equity.

Order book is intact and large. 7.9 GW non-DCR order book is not shrinking; customer delays are deferring delivery, not cancelling. Distribution and mid-market ramps provide pricing power (₹0.50–1.50/Wp premium vs large accounts) that does not exist in utility segment. Long-term, this mix shift is value-accretive.

Margin collapse is near-term structural, not cyclical recovery. 210 GW national capacity vs 45–50 GW annual demand = 4.7x oversupply. No pricing power until capacity rationalization (industry M&A, bankruptcies) or demand surge (unlikely before FY29). Vikram's 8.1% EBITDA margin matches oversupply reality; peers' 9–10% is not sustainable either.

FY27 margin recovery is mathematically impossible. Q1 set the baseline at 8.1%. DCR (76 MW, 7.5% of volume) would need to grow to 20–25% mix and deliver 15% margin (vs base 8%) to lift full-year EBITDA by 5 percentage points. Current trajectory suggests 8–9% for full year. Cell margin benefit is 12+ months away (Q4 FY27 commissioning, FY28 ramp).

Prior guidance credibility is shattered. ₹1,500–1,600 Cr FY27 EBITDA was a firm prior call. Q1's trajectory (66% miss) and management's deferral of H1 guidance signals a 25–35% downward revision is coming. Investors who acted on prior guidance now face a material credibility reset.

ALMM 2 policy remains a binary uncertainty. Cell mandate has been deferred June 1 → July 18 → Dec 31. Further deferrals would trigger another customer procurement pause. C&I non-DCR demand unlock (estimated 15 GW/year) is now contingent on Dec 31 finalization — not assured.

Capex ₹10,000 Cr over 2 years carries execution risk. Wafer-ingot (₹5,600 Cr), BESS cell plant (₹700–800 Cr), and cell ramp (₹3,000 Cr) are multi-year bets. Delays, cost overruns, or policy shifts could require equity raise or breach 70:30 debt-equity target. High leverage in a commodity cycle is a real risk.